Clinical Trial Update: A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating disitamab vedotin with trastuzumab and tislelizumab versus chemotherapy with trastuzumab (with or without pembrolizumab) in HER2-high a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Carcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Pembrolizumab (pembrolizumab)
• Tislelizumab (tislelizumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Gastric Carcinoma | Phase 3 | Status: RECRUITING